Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Baxter
Colorcon
Medtronic
Express Scripts

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR NADOLOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nadolol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00390546 ↗ Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia Completed The Hospital for Sick Children Phase 3 2006-10-01 This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
NCT00390546 ↗ Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia Completed University of Utah Phase 3 2006-10-01 This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
NCT00390546 ↗ Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia Completed University of British Columbia Phase 3 2006-10-01 This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nadolol

Condition Name

Condition Name for Nadolol
Intervention Trials
Healthy 2
Heart Disease 2
Heart Failure 2
Cardiac Failure 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nadolol
Intervention Trials
Hypertension 5
Hemorrhage 4
Liver Cirrhosis 3
Hypertension, Portal 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nadolol

Trials by Country

Trials by Country for Nadolol
Location Trials
United States 33
Canada 6
Spain 2
China 1
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nadolol
Location Trials
Ohio 4
Missouri 3
New York 3
North Carolina 2
Virginia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nadolol

Clinical Trial Phase

Clinical Trial Phase for Nadolol
Clinical Trial Phase Trials
Phase 4 10
Phase 3 3
Phase 2 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nadolol
Clinical Trial Phase Trials
Completed 14
Unknown status 4
Enrolling by invitation 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nadolol

Sponsor Name

Sponsor Name for Nadolol
Sponsor Trials
Invion, Inc. 3
The Hospital for Sick Children 3
National Science Council, Taiwan 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nadolol
Sponsor Trials
Other 22
Industry 11
NIH 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Baxter
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.